Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)

<p>Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous and meaningful improvements in bone mineral density (BMD) Ultragenyx hosting Analyst Day on Monday, October 16 at 8:30 a.m. ET NOVATO, Calif., VANCOUVER, British Columbia and LONDON, Oct. 14, 2023 (GLOBE NEWSWIRE) &#8212; [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/ultragenyx-and-mereo-biopharma-announce-interim-phase-2-data-from-phase-2-3-orbit-study-demonstrating-setrusumab-ux143-significantly-reduced-fracture-rates-in-patients-with-osteogenesis-imperfecta/">Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>